Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
revumenib + chemotherapy
- Development stage
- Unknown
- Lead developer
- Syndax Pharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Intrathecal, Via Nasogastric, Nasojejunal, Nasoduodenal, Gastrostomy Tube
01
Overview
**Revumenib + chemotherapy** is an investigational combination regimen consisting of revumenib, an oral menin inhibitor, together with various standard chemotherapeutic agents. Revumenib inhibits the interaction between menin and mixed-lineage leukemia 1 (KMT2A, formerly MLL), disrupting a critical oncogenic pathway in acute leukemias harboring KMT2A rearrangements or NPM1 mutations. The combination is primarily developed for relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)—especially in patients with KMT2A rearrangements or NPM1 mutations. Chemotherapy backbones studied with revumenib include cytarabine, daunorubicin, vincristine, prednisone or prednisolone, calaspargase pegol, methotrexate, hydrocortisone, fludarabine, and midostaurin (for FLT3-mutated AML)[1][5]. The combination aims to improve remission rates and outcomes in young children and adults for whom prognosis is otherwise poor.
- Other names
- revumenib plus chemotherapyrevumenib combination chemotherapy
02
Targets
MEN1 (Menin)
Beyond the preview
Go deeper on revumenib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on revumenib + chemotherapy.